BRNS
Barinthus BiotherapeuticsBRNS
BRNS
$1.37
6.16%
Market Cap: 53.5M
About: Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Employees: 130
0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
–
News positive %
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 15 [Q4 2023] → 15 (+0) [Q1 2024]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.28% less ownership
Funds ownership: 25.2% [Q4 2023] → 24.92% (-0.28%) [Q1 2024]
42% less capital invested
Capital invested by funds: $36.5M [Q4 2023] → $21.3M (-$15.2M) [Q1 2024]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Research analyst outlook
6 Wall Street Analysts provided 1 year price forecasts over the past 6 months
Low target
$3
119%
upside
Avg. target
$7.17
423%
upside
High target
$8
484%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Barclays Carter Gould | 119%upside $3 | Overweight Maintained | 13 Jun 2024 |
HC Wainwright & Co. Yi Chen | 484%upside $8 | Buy Reiterated | 7 Jun 2024 |
HC Wainwright & Co. Yi Chen | 484%upside $8 | Buy Reiterated | 16 May 2024 |
HC Wainwright & Co. Yi Chen | 484%upside $8 | Buy Reiterated | 22 Apr 2024 |
HC Wainwright & Co. Yi Chen | 484%upside $8 | Buy Reiterated | 19 Apr 2024 |